 

Active ingredient: Atovaquone 

 

Form/Route: Suspension/Oral 

 

Recommended study: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two way crossover in-vivo 

Strength: 750 mg/5 mL (750 mg dose) 

Subjects: Healthy males and nonpregnant females, general population 

Additional Comments: 




________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two way crossover in-vivo 

Strength: 750 mg/5 mL (750 mg dose) 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: 




________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Atovaquone in plasma. 

 

Bioequivalence based on (90% CI): Atovaquone. 

 

Waiver request of in-vivo testing: N/A 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm . Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 

 

Please note that a dosage unit for a suspension is the labeled strength (ml). A total of 12 units 
from 12 different bottles should be used. 


